US EditionCaregen Extends CG-P5 Clinical Trial Schedule
Summary by businesskorea.co.kr
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Caregen Extends CG-P5 Clinical Trial Schedule
Caregen (CEO Yong-ji Chung) announced on June 26 through a public disclosure that the schedule for the Phase 1 clinical trial of CG-P5, a new drug for wet age-related macular degeneration under development, has been extended to October 31, 2025 in the United States. The clinical trial has been conducted at seven institutions in the United States since July 2023, with a total of 45 subjects enrolled. Caregen explained that the trial has been prog…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
